ライフサイエンスコーパス: radiolabel

1 addition, these drugs are relatively easy to radiolabel.

2 simplified design for single-step kit-based radiolabeling.

3 hydrazino-nicotinamide (S-HYNIC) followed by radiolabeling.

4 ers, using positron emission tomography with radiolabeled [11C]ABP688, which binds to an allosteric s

5 Studies with doubly radiolabeled 16 provide a proof-of-concept for the use o

6 hereby inflammatory activation and uptake of radiolabeled 2-deoxyglucose was assessed before and afte

7 Both constructs rapidly radiolabeled (225) Ac in just minutes at RT, and macropa

8 The uptake of radiolabeled 28H1 in inflamed joints (percentage injecte

9 Uptake assays with yeast cells and radiolabeled (32)P revealed that PvPht1;3 and AtPht1;5 h

10 velopment of an N-terminally truncated GAD65 radiolabel, (35)S-GAD65(96-585), which improved the perf

11 This yielded radiolabeled [(64)Cu]-NPs of uniform shape and size with

12 The aim of this study was to radiolabel a novel bis-deuterium substituted l-deprenyl

13 In vitro radiolabeled acetate incorporation assays confirm that p

14 Anti-CD56 mAb was radiolabeled, achieving a radiochemical purity of more t

15 nostic marker and demonstrate the utility of radiolabeled ACKR3-mAb for in vivo visualization of ACKR

16 Here we report the evaluation of a radiolabeled ACKR3-targeted monoclonal antibody (ACKR3-m

17 Here we present two methods for radiolabeling adeno-associated virus (AAV), one of the m

18 (68)Ga-ABY-025 is a radiolabeled Affibody molecule for in vivo diagnosis of

19 , it was thought that internalization of the radiolabeled agonist was mandatory for sstr-mediated ima

20 d into a protocol for the synthesis of (18)F-radiolabeled aliphatic CF3-containing compounds, enablin

21 t translation assays, polysome profiling and radiolabeled amino acid incorporation, we show that redu

22 transport studies with aap8 mutants fed with radiolabeled amino acids and by leaf exudate analyses.

23 demonstrated good agreement with established radiolabelled amino acid incorporation assays: TGFbeta1

24 ocholate administered in choleretic or trace radiolabel amounts (around 60%, P < 0.05).

25 he purified (67)Cu material was then used to radiolabel an anti-EGFR antibody, Panitumumab, and injec

26 A radiolabeled analog, [(125) I]-PD-sauvagine, with high s

27 The radiolabeled analogue was bound and internalized by LNCa

28 ous system, numerous adrenoceptor drugs were radiolabeled and potent radioligands were prepared in or

29 onsidered to have non-obvious strategies for radiolabeling and require a more customized approach.

30 Here, we use electrophysiological, radiolabeled, and fluorescence-based transport assays in

31 )Zr-DFO-AMG102 was successfully synthesized, radiolabeled, and validated in vitro and in vivo to sele

32 , monitored wax biosynthesis through [(14)C]-radiolabeling, and sequenced the transcriptome.

33 the significantly higher tumor uptake of the radiolabeled antagonist than of the agonist as measured

34 Two "first-generation," directly radiolabeled anti-CD20 antibodies, (131)iodine-tositumom

35 k after HSC transplantation using the (89)Zr-radiolabeled anti-CD4 and -CD8 cDbs.

36 he aim of this study was to assess whether a radiolabeled anti-FAP antibody could be used to monitor

37 ume in mice can be measured by PET-CT with a radiolabeled anti-PD-L1 antibody.

38 h after injection) than previously reported radiolabeled antibodies (>24 h after injection).

39 n practice, but also could spread the use of radiolabeled antibodies beyond locations with cyclotron

40 Using radiolabeled antibodies or fragments derived from them,

41 otestosterone ((18)F-FDHT), and a variety of radiolabeled antibodies targeting downstream effectors,

42 ct platform not only could enable the use of radiolabeled antibodies to become a common practice, but

43 Immunoreactive preparations of the radiolabeled antibodies were injected into NCr nu/nu mic

44 Here, we evaluated (64)Cu-rituximab, a radiolabeled antibody specifically targeting the human B

45 Background uptake of the radiolabeled antibody was low, resulting in excellent im

46 t with previously reported studies with this radiolabeled antibody.

47 njugation, providing a promising alternative radiolabeling approach that maintains the native in vivo

48 ver, we employed shRNA library screening and radiolabeling approaches, as well as in vitro and in viv

49 8)F-fluoroethyl)-l-tyrosine ((18)F-FET) is a radiolabeled artificial amino acid used in PET for tumor

50 , we explored the in vivo biodistribution of radiolabeled asparaginase, using a combination of imagin

51 alogue (MANT-ATP) and by UV cross-linking of radiolabeled ATP.

52 (18)F-PF-05270430 was radiolabeled by 2 methods via nucleophilic substitution

53 [(18)F]6b (KD = 12.3 nM) was radiolabeled by a two-step procedure using a microwave s

54 Biodistribution studies with radiolabeled CAF09 and a surface-adsorbed model antigen

55 Here we develop a radiolabeled camelid single-domain antibody (anti-PD-L1

56 Finally, droplets encapsulating radiolabeled cancer cells allowed, for the first time, t

57 Radiolabeled cancer-seeking agents, however, undergo deg

58 Selected radiolabeled candidates were evaluated in vitro and in v

59 , CdWO4) is placed in close proximity to the radiolabeled cells, where it converts the radioactive de

60 ailure to identify the SLN relative to using radiolabeled colloid +/- blue dye (P = 0.006; OR = 3.82;

61 was higher when mapping was performed using radiolabeled colloid alone or with blue dye compared wit

62 te was 78.6% with blue dye alone; 91.4% with radiolabeled colloid and 93.8% with dual mapping agents.

63 nt imaging properties but greatly simplified radiolabeling compared with other (68)Ga-PSMA conjugates

64 In theranostics, radiolabeled compounds are used to determine a treatment

65 Radiolabelled compounds, typically those that contain (1

66 , we synthesized two different types of dual-radiolabeled conjugates, including 1) (111)In-2P-EPI-(12

67 selective picomolar inhibitor of MMP-13, the radiolabeled counterpart [(18)F]4 was successfully synth

68 half-times and higher liver uptake than the radiolabeled counterparts.

69 sing candidates for the development of (18)F-radiolabeled COX-2 inhibitors for imaging purposes with

70 Based on promising experiences with a radiolabeled CXCR4 ligand ((68)Ga-pentixafor) for diagno

71 Molecular imaging with recently developed radiolabeled CXCR4 ligands could facilitate the selectio

72 tently and equally suppressed the release of radiolabelled d-[(14) C]aspartate and [(3) H]taurine.

73 characterization of a M2R subtype-preferring radiolabeled dibenzodiazepinone-type antagonist ([(3)H]U

74 Radiolabeled drug quantified bulk delivery and fluoresce

75 the study of small-molecule transport (e.g., radiolabeled drugs, metabolic precursors and nuclear med

76 The small fast-clearing radiolabelled effector molecules with a complementary fu

77 5 degrees C for 2h) of (52)Mn gave excellent radiolabeling efficiencies of 97-100% and 98-100% respec

78 of one radiolabeling precursor, which can be radiolabeled either with (68)Ga for diagnosis or with (1

79 of the techniques, the different methods of radiolabeling erythrocytes, the procedure, useful indica

80 Radiolabeling experiments further demonstrated MltG-depe

81 On the contrary, radiolabeling experiments revealed impaired synthesis of

82 (55)Fe-radiolabeling experiments with human cells depleted of C

83 Using co-immunoprecipitation and (55)Fe-radiolabeling experiments, we therefore studied the role

84 cintigraphy quantified the uptake of studied radiolabelled f-MWNT in the whole brain parenchyma and c

85 We have developed a novel radiolabeled FFA2 antagonist to probe ligand binding to

86 for quantitative metabolite profiling, i.e., radiolabeling followed by high-performance liquid chroma

87 ration, and pathways were monitored by (14)C-radiolabelling followed by high-voltage electrophoresis.

88 Natural and synthetic amino acids radiolabeled for PET imaging have been investigated in p

89 However, although a radiolabelled form of a related antagonist, [(3)H]G9543,

90 In vitro enzyme analysis using a radiolabel-free assay revealed distinct substrate specif

91 Incorporation of radiolabel from either (55)Fe(2+) or (59)Fe(3+) into cel

92 Radiolabeled galactose saturation binding experiments in

93 For the treatment of prostate cancer, radiolabeled gastrin-releasing peptide receptor (GRPr) a

94 functional studies included incorporation of radiolabeled Glc, linkage analysis, and imaging of cellu

95 rinsulinemic-euglycemic clamps combined with radiolabeled glucose to assess liver and muscle insulin

96 vivo and in vitro labeling experiments using radiolabeled GPI precursors showed that GPI underglycosy

97 overexpressed in human prostate cancer, and radiolabeled GRPr affinity ligands have shown promise fo

98 As a result of our investigations, a novel radiolabeled GRPr agonist with a high tumor uptake and a

99 tive breast cancer, using recently developed radiolabeled GRPR ligands.

100 Pharmacological studies using radiolabeled guanosine 5'-3-O-([(35)S]thio)triphosphate

101 nnocuous, appending nanoparticles with these radiolabeling handles can have dramatic effects on impor

102 Heat-induced radiolabeling (HIR) yielded (89) Zr-Feraheme (FH) nanopa

103 ccinyl-glycine (HSG) trivalent BsMAb TF2 and radiolabeled HSG peptide (IMP288) present good features

104 Radiolabeling identified sn-2 monoacylglycerol as an ini

105 These radiolabelled imaging probes were injected i.v. into wil

106 e sensing avoids drawbacks of currently used radiolabel-immunoassays for renin.

107 The ability to be radiolabeled in such a straightforward but very robust w

108 ter conjugation to a DFO chelator and (89)Zr radiolabeling, in assays including cell uptake, internal

109 The position of the radiolabel influences targeting as well, although to a l

110 This is further supported by transfer of radiolabels into product from both alpha and gamma phosp

111 Efficient radiolabeling is directly performed with aqueous [(18)F]

112 only by immunoprecipitation from extracts of radiolabeled islet or neuronal cells.

113 n emission tomography (PET) TrkB/C-targeting radiolabeled kinase inhibitor lead.

114 he FP an anti-chelated radiometal trap for a radiolabeled ligand (yttrium[Y]-DOTA) captured by a very

115 an uptake as percentage injected activity of radiolabeled ligand per gram of tissues (%IA/g) was eval

116 mproved on administration of higher doses of radiolabeled ligand, suggesting that certain binding sit

117 d rapid internalization (80-95%, 2 h) of the radiolabeled ligands in PSMA(+) cells.

118 Positron emission tomography (PET) using radiolabeled ligands selective for the 18 kDa translocat

119 Radiolabeled ligands specific for cholinesterases have p

120 Therefore, we employed these four radiolabeled liposome types as platforms to demonstrate

121 We report optimized protocols for radiolabeling liposomes with (52)Mn, through both remote

122 68Ga- and 89Zr-radiolabeled [Lys40-(AHX-DFO)NH2]exendin-4 exhibit chara

123 nformation on the whole-body distribution of radiolabeled mAbs and antibody-related therapeutics.

124 ed the kinetics of intraperitoneally infused radiolabeled mAbs in humans and showed the benefit of in

125 Our results show that high-specific-activity radiolabeled mAbs that are bound to a tumor surface will

126 The dose from cell-bound radiolabeled mAbs will be negligible by comparison.

127 Native gel-shift assays revealed a shift in radiolabeled MALAT1 ENE+A RNA upon addition of HEK293T c

128 educing terminus based on the degradation of radiolabeled maltodextrins, although recent reports chal

129 ine) of solids T1/2 (time taken for half the radiolabelled meal to empty from the stomach), measured

130 Radiolabeled metabolites were determined from blood samp

131 l advanced models that account for uptake of radiolabeled metabolites were evaluated, including a var

132 We present a novel solid-phase based (45)Ti radiolabeling methodology and the implementation of (45)

133 generated a range of innovative chelate-free radiolabeling methods that exploit intrinsic chemical fe

134 s analytical tools to quantify the amount of radiolabeled micropollutant available in solution.

135 Intracellular accumulation of radiolabeled MLF was significantly higher in ABCA3(KD) m

136 This approach can be established using radiolabeled MMP inhibitors (MMPIs) as tracers for the d

137 Radiolabeled molecular imaging tracers directed toward c

138 We systematically screened 961 random radiolabeled molecules in silico as substrates for essen

139 ential losses were tracked using three model radiolabeled molecules, namely BPA, DEHP and 4n-NP.

140 ine concerned with the use of radioisotopes, radiolabelled molecules, nanoparticles, or microparticle

141 Intraperitoneally administered radiolabeled monoclonal antibodies (mAbs) have been test

142 the biokinetics of intraperitoneally infused radiolabeled monoclonal antibodies (mAbs) were modeled u

143 Therapy of cancer with radiolabeled monoclonal antibodies has produced impressi

144 Fluorescent and radiolabeled MSCs (1x10(6)) were injected 24 hours post-

145 we report on the application of the (111)In-radiolabeled Nanobody for SPECT/CT imaging of PCa.

146 Classic methods for radiolabeling nanoparticles involve functionalization of

147 ry of 9 mechanistically distinct methods for radiolabeling nanoparticles is presented.

148 A central challenge in radiolabeling nanoparticles is to identify alternative c

149 It highlights current examples of radiolabeled nanoparticulate probes in preclinical cardi

150 timizing the tumor targeting properties of a radiolabeled [Nle(14)]BBN(7-14) moiety, novel BBN(7-14)-

151 mpathetic nerve traffic, and measurements of radiolabeled norepinephrine spillover.

152 We aimed to determine whether radiolabeled NPs could be used as a noninvasive, highly

153 Radiolabeled NSCs were administered to glioma-bearing mi

154 on profile compared with previously reported radiolabeled NTR1 ligands, (111)In-3BP-227 is an ideal c

155 e, 1-step, room-temperature syringe-and-vial radiolabeling of (68)Ga radiopharmaceuticals.

156 nation at RT was successfully applied to the radiolabeling of [(18)F]-2-fluoroethylamines in which th

157 20.3 min) possesses the unique potential for radiolabeling of any biological, naturally occurring, or

158 Our method does not require radiolabeling of any components and therefore can be use

159 ortant and versatile building blocks for the radiolabeling of biomolecules via Huisgen cycloaddition

160 eous sodium chloride (NaCl)-based method for radiolabeling of chelator-modified peptides for molecula

161 Radiolabeling of MSB0010853 with (89)Zr was performed wi

162 Radiolabeling of NOTA-AE105 with (64)Cu and (68)Ga was s

163 development of these modalities through the radiolabeling of somatostatin analogs with various radio

164 The TF-targeted tracer was developed through radiolabeling of the anti-human TF monoclonal antibody (

165 Radiolabeling of the prostate-specific membrane antigen

166 Radiolabeling of VUF11211 gave [(3)H]VUF11211, which in

167 ned its ability to metabolically incorporate radiolabeled oleic acid into TAG, accumulate lipid dropl

168 s compared with that of octreotate with only radiolabel or only optical label.

169 r determining target occupancy include using radiolabeled or irreversible surrogates, which can be te

170 which the CCSD was orally administered via a radiolabelled osmotic tablet formulation.

171 acid oxidation in primary hepatocytes using radiolabeled palmitate and in mice using indirect calori

172 Radiolabeled PEG-GIRLRG could be used to target various

173 the pharmacokinetics and biodistribution of radiolabeled pembrolizumab in vivo, while providing deta

174 e of the study was to analyze the ability of radiolabeled pentixafor to detect CXCR4 expression on in

175 rm a comparative effectiveness evaluation of radiolabelled peptide p5+14 with p5 and SAP, in amyloid-

176 Radiolabeled peptides for tumor imaging with PET that ca

177 ically stable trans-amide bond surrogates in radiolabeled peptides in order to improve their tumor ta

178 arameters such as the internalization of the radiolabeled peptides into PC3 and AR42J tumor cells, th

179 eptides with radiometals and applications of radiolabeled peptides will not be treated herein.

180 The system provides radiolabeled peptides with high (>98%) radiochemical pur

181 s were performed 96 h after injection of the radiolabeled peptides.

182 A radiolabeled peptidomimetic integrin antagonist, (111)In

183 through optical imaging (OI) and the use of radiolabelled polymer-drug conjugates demonstrated conju

184 recurrent prostate cancer by the use of one radiolabeling precursor, which can be radiolabeled eithe

185 e not inhibiting DNA biosynthesis using (3)H-radiolabeled precursors in macromolecular synthesis inhi

186 c strategy that affords modular synthesis of radiolabeling precursors via a copper-catalyzed 'click'

187 New radiolabeled probes for positron-emission tomography (PE

188 e used to obtain functional information from radiolabeled probes using multimodal imaging.

189 r potentially nucleophilic residues, and the radiolabeled products were synthesized and purified in l

190 Radiolabeled prostate-specific membrane antigen (PSMA) l

191 r oral administration, using highly purified radiolabeled PrP(Sc).

192 Binding of radiolabeled pyruvate was found for full-length YehU in

193 ers, but irrespective of the particle class, radiolabeling remains a key step.

194 Radiolabeled rHDL nanoparticles incorporating the long-l

195 Methods:(11)C-radiolabeled sarcosine was tested as a new PET imaging p

196 er for imaging PSMA expression that could be radiolabeled simply by addition of (68)Ga generator elua

197 ctive decays occurring stochastically within radiolabeled single-cells into an integrated, long-lasti

198 g CT, MRI, and (18)F-FDG PET, as well as new radiolabeled small molecules, antibodies, and antibody f

199 rting of single cells based on the uptake of radiolabeled small molecules.

200 A radiolabeled small-molecule GPR44 antagonist, [(11)C]AZ1

201 nt the design and synthesis of novel gallium-radiolabeled small-molecule sulfonamides targeting CA IX

202 ction) between the tumour bound antibody and radiolabelled small molecules.

203 atum corneum exposed to aqueous solutions of radiolabeled sodium chloride, tetraethyl ammonium bromid

204 Radiolabeled somatostatin (sst) receptor agonists are in

205 preliminary clinical evidence indicates that radiolabeled somatostatin (sst) receptor antagonists per

206 eatment of neuroendocrine tumors (NETs) with radiolabeled somatostatin analogs represent a milestone

207 (68)Ga-DOTATOC and (68)Ga-DOTATATE are radiolabeled somatostatin analogs used for the diagnosis

208 Preoperative guidance with radiolabeled somatostatin analogs, commonly used for NET

209 ocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs.

210 peptide receptor radionuclide therapy using radiolabeled somatostatin analogs.

211 peptide receptor radionuclide therapy using radiolabeled somatostatin receptor (SSTR) agonists are s

212 Radiolabeled somatostatin receptor (SSTR) antagonists ha

213 r QNB or NMS slow down dissociation of their radiolabeled species from all five subtypes of muscarini

214 )-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH2)), a novel radiolabeled sst receptor antagonist with a high affinit

215 Furthermore, binding of the radiolabeled SSTR agonist and antagonist was analyzed in

216 mparing the therapeutic antitumor effects of radiolabeled SSTR agonists versus antagonists are lackin

217 f peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [(90)Y-DOTA(0),Tyr(3

218 studies have demonstrated the superiority of radiolabeled SSTR antagonists for imaging purposes, desp

219 who proposed in 2006 the paradigm shift that radiolabeled sstr antagonists may perform better than ag

220 these results, we concluded that the use of radiolabeled SSTR antagonists such as JR11 might enhance

221 iscuss the development and current status of radiolabeled sstr antagonists.

222 Non-traditional radiolabelling strategies are employed to enable an auto

223 Radiolabeling studies showed that macropa, at submicromo

224 Radiolabelling studies show that PCK predominantly allow

225 Here, we describe a general method for using radiolabeled substrate flux assays to determine coupling

226 PbENT1 in purine auxotrophic yeast and used radiolabeled substrate uptake to characterize its functi

227 sociations of SLC2A14 with IBD.The uptake of radiolabeled substrates into Xenopus laevis oocytes expr

228 easured in the isolated perfused heart using radiolabelled substrates.

229 Radiolabeled synthetic fragments of the antimicrobial pe

230 lecular imaging of PARP using fluorescent or radiolabeled tags has followed on the success of therape

231 ncluding the precursor preparation and (18)F radiolabeling, takes 7-10 d.

232 In vivo biodistribution of radiolabeled targeted Pam-NPs demonstrated enhanced bone

233 oup II (n=5) received a blocking dose of non-radiolabeled TCP-1.

234 is exemplified by measurements made on three radiolabeled test compounds--caffeine, testosterone, and

235 ng confirmed the predominant accumulation of radiolabeled tetrazine in the tumor and low nontumor ret

236 es the number of TCO groups per diabody) and radiolabeled tetrazine to optimize the TCO modification

237 Critically, both radiolabeled tetrazines showed negligible uptake in the

238 We have radiolabeled the PD-L1-binding Affibody molecule NOTA-ZP

239 B0010853 biodistribution and tumor uptake by radiolabeling the Nanobody construct with (89)Zr.

240 ions, we synthesized a series of candidates, radiolabeled them with fluorine-18 radioisotope, and det

241 ction, which significantly increases overall radiolabeling time and causes radioactivity loss.

242 Radiolabeling to produce (18)F-SO3F(-) was simple and af

243 All f-MWNTs were radiolabelled to facilitate quantitative analyses by gam

244 highly selective CB2R inverse agonist, as a radiolabeled tool compound.

245 e localization was shown in tumors, when the radiolabeled tracer was injected 4 h after an injection

246 Radiolabel transport assays show that PhpCAT exports all

247 Radiolabel uptake in prominent lesions was measured as S

248 spectrometric, fluorescence microscopic and radiolabeled uptake evidence that trehalose traverses th

249 Radiolabeled urea-based low-molecular weight inhibitors

250 pling partners, make it amenable for in vivo radiolabelling using pretargeting methodologies, which a

251 The introduction of radiolabels using synthetic chemistry enables the direct

252 A URAT1 binding assay using radiolabeled verinurad revealed that distinct URAT1 inhi

253 rgeted imaging of alpha V beta 3 activity (a radiolabeled version, (64)Cu-NOTA-PEG4-cRGD2, for PET im

254 Azide functionalized NPs were radiolabeled via a "click" reaction with copper-64 ((64)

255 Radiolabeling was accomplished by a nucleophilic substit

256 Radiolabeling was accomplished with high radiochemical y

257 Radiolabeling was achieved via standard electrophilic io

258 Radiolabeling was complete (>95%) within 5 min at room t

259 ectrospray ionization-mass spectrometry, and radiolabeling was monitored by instant thin-layer chroma

260 Radiolabeling was performed by pumping (89)Zr-oxalate an

261 n barrier penetration, and the ability to be radiolabeled with (11)C.

262 1)In-2P-EPI-(125)I (polymeric carrier 2P was radiolabeled with (111)In and drug EPI with (125)I), and

263 in vivo by injection of pegylated liposomes radiolabeled with (111)In.

264 This compound was subsequently rapidly radiolabeled with (123)I and purified by high-performanc

265 5)I-2P-EPI-(111)In (polymeric carrier 2P was radiolabeled with (125)I and drug EPI with (111)In).

266 In addition, ACKR3-mAb was radiolabeled with (125)I and evaluated by SPECT imaging

267 n with an albumin-binding domain (ABD), were radiolabeled with (125)I and intravenously injected into

268 11B6 was radiolabeled with (177)Lu through the CHX-A''-DTPA chela

269 luate novel AD diagnostic agents that can be radiolabeled with (64)Cu, a radionuclide with a half-lif

270 DOTA-alendronate was synthesized, radiolabeled with (64)Cu, and administered to normal or

271 esized, conjugated to a copper chelator, and radiolabeled with (64)Cu.

272 NeoBOMB1 was radiolabeled with (67/68)Ga, (111)In, and (177)Lu accord

273 rea-based PSMA inhibitor was synthesized and radiolabeled with (68)Ga by adding generator eluate dire

274 chelator-free method, the nanoparticles were radiolabeled with (68)Ga without having to alter their s

275 -10 was conjugated with a DFO B chelator and radiolabeled with (89)Zr to give formulated (89)Zr-DFO-A

276 MSB0010853 was radiolabeled with (89)Zr.

277 tuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr.

278 tuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr.

279 The anti-CD56 monoclonal antibody (mAb) was radiolabeled with 99mTc, and in vitro quality controls w

280 Results:(64)Cu-DOTA-alendronate was radiolabeled with a 98% yield.

281 All 3 tracer candidates were radiolabeled with a PET nuclide and tested in vivo in ta

282 , RO6931643, and RO6924963 were successfully radiolabeled with a PET nuclide at high specific activit

283 bladder with fluorescent-tagged tilmanocept, radiolabeled with both (68)Ga and (99m)Tc.

284 The most promising ligand 6a was radiolabeled with carbon-11 to yield 16 ([(11)C]RSR-056)

285 core have been synthesized and successfully radiolabeled with carbon-11, fluorine-18, and gallium-68

286 Two of them were radiolabeled with fluorine-18, and their biodistribution

287 Radiolabeled with iodine-125, Rho-FF-Van shows strong ra

288 FVIIai was radiolabeled with N-succinimidyl 4-(18)F-fluorobenzoate

289 glutaric acid-4,7-diacetic acid (NODAGA) and radiolabeled with the positron-emitting radionuclide (64

290 The mouse antihuman CD30 antibody AC-10 was radiolabeled with the positron-emitting radionuclide (89

291 Others are radiolabeled with the short-half-life positron emitter c

292 rolled conjugation and polymerization before radiolabeling with (64)Cu for PET imaging in an apolipop

293 lator p-SCN-Bn-DFO was conjugated to AMG102, radiolabeling with (89)Zr was performed in high radioche

294 ted to the HER2 mAb trastuzumab, followed by radiolabeling with (89)Zr.

295 DFO-p-benzyl-isothiocyanate (DFO-Bz-NCS) for radiolabeling with (89)Zr.

296 dnones was further highlighted by successful radiolabeling with [(18) F]Selectfluor.

297 Radiolabeling with long-lived positron emission tomograp

298 pembrolizumab in vivo, accomplished through radiolabeling with the positron emitter (89)Zr.

299 his peptide, it was conjugated with NOTA and radiolabelled with copper-64.

300 -methoxyphenyl)iodonium salt and its [(18)F] radiolabeling within a one-step, fully automated and cGM